SEC Form 4 · accession 0001127602-16-056903
HAEMONETICS CORP · HAE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Simon
Officer — President & CEO
Period of report
Jun 29, 2016
Accepted (ET)
Jul 1, 2016 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000313143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 29, 2016 | A | 45,867 | $0.01 | A | 45,867 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $28.615 | Jun 29, 2016 | A | 196,746 | A | Jun 29, 2017 | Jun 29, 2023 | Common Stock | 196,746 | 196,746 | D |
| Performance SharesF3 | $0.00 | Jun 29, 2016 | A | 26,210 | A | Mar 30, 2019 | Dec 31, 2019 | Common Stock | 26,210 | 26,210 | D |
| Performance SharesF4 | $0.00 | Jun 29, 2016 | A | 65,525 | A | Mar 30, 2019 | Dec 31, 2019 | Common Stock | 65,525 | 91,735 | D |
Explanation of responses
- F1Restricted Stock Unit grants which vest 25% per year over 4 years following the grant date. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- F2Grants of right to buy shares of common stock which are exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant. Grants were made under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- F3This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on measurements of Haemonetics' financial and operational performance. The number of Performance Share Units (and therefore the number of shares payable) will depend on performance during Haemonetics' 2017, 2018 and 2019 fiscal years. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could be up to 150% of the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.
- F4This grant of Performance Share Units represents a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to companies in the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance during a three year period beginning April 3, 2016. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan.